Ninety One UK Ltd reduced its stake in Iqvia Holdings Inc (NYSE:IQV) by 17.9% during the second quarter, Holdings Channel.com reports. The firm owned 947,818 shares of the medical research company’s stock after selling 207,335 shares during the quarter. Ninety One UK Ltd’s holdings in Iqvia were worth $134,476,000 as of its most recent filing with the SEC.
A number of other institutional investors and hedge funds also recently modified their holdings of IQV. RMR Wealth Builders bought a new position in shares of Iqvia during the 2nd quarter valued at approximately $25,000. Fortis Advisors LLC acquired a new position in shares of Iqvia in the 1st quarter valued at $32,000. Carroll Financial Associates Inc. raised its stake in Iqvia by 90.3% in the 2nd quarter. Carroll Financial Associates Inc. now owns 236 shares of the medical research company’s stock worth $33,000 after acquiring an additional 112 shares during the last quarter. Shine Investment Advisory Services Inc. acquired a new stake in Iqvia during the 2nd quarter worth about $35,000. Finally, Citizens Financial Group Inc RI lifted its position in Iqvia by 69.4% during the 1st quarter. Citizens Financial Group Inc RI now owns 376 shares of the medical research company’s stock worth $41,000 after acquiring an additional 154 shares during the period. Institutional investors and hedge funds own 88.65% of the company’s stock.
In other Iqvia news, insider Ari Bousbib sold 46,080 shares of the stock in a transaction that occurred on Wednesday, July 22nd. The stock was sold at an average price of $160.00, for a total transaction of $7,372,800.00. Following the completion of the transaction, the insider now owns 698,115 shares of the company’s stock, valued at $111,698,400. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Group Holdings (Sbs) Advis Tpg sold 2,919,051 shares of the firm’s stock in a transaction that occurred on Tuesday, July 28th. The shares were sold at an average price of $159.12, for a total value of $464,479,395.12. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 3,034,251 shares of company stock worth $483,026,134. Insiders own 1.40% of the company’s stock.
IQV traded up $3.06 during trading on Tuesday, hitting $164.71. The company’s stock had a trading volume of 766,000 shares, compared to its average volume of 1,434,445. The firm has a market capitalization of $30.92 billion, a price-to-earnings ratio of 242.22, a P/E/G ratio of 2.82 and a beta of 1.33. Iqvia Holdings Inc has a twelve month low of $81.79 and a twelve month high of $170.51. The business’s fifty day simple moving average is $160.21 and its 200 day simple moving average is $140.52. The company has a current ratio of 1.10, a quick ratio of 1.09 and a debt-to-equity ratio of 2.04.
Iqvia (NYSE:IQV) last announced its earnings results on Wednesday, July 22nd. The medical research company reported $1.18 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.06 by $0.12. The firm had revenue of $2.52 billion for the quarter, compared to analyst estimates of $2.41 billion. Iqvia had a return on equity of 17.90% and a net margin of 1.21%. During the same quarter last year, the firm posted $1.53 EPS. As a group, equities research analysts forecast that Iqvia Holdings Inc will post 5.72 earnings per share for the current fiscal year.
IQVIA Holdings Inc provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Further Reading: What are the risks of holding treasury bonds?
Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Iqvia Holdings Inc (NYSE:IQV).
Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.